John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Yuguero O, Marsal JR, Esquerda M, Galvan L, Soler-Gonzalez J. Cross-sectional study of the association between empathy and burnout and drug prescribing quality in primary care. Prim Health Care Res Dev. 2019 Oct 30;20:e145. doi: 10.1017/S1463423619000793
Norwood P, Correia I, Veiga P, Watson V. Patients' experiences and preferences for primary care delivery: a focus group analysis. Prim Health Care Res Dev. 2019 Jun 24;20:e106. doi: 10.1017/S1463423619000422
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Maskey MK, Baral KP, Shah R, Shrestha BD, Lang J, Rothman KJ. Field test results of the motherhood method to measure maternal mortality. Ind Med Gaz. 2011 Jan 1;133(1):64-9.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Roland M, Campbell S, Baliey N, Whalley D, Sibbald B. Financial incentives to improve the quality of primary care in the UK: predicting the consequences of change. Prim Health Care Res Dev. 2006 Jan 1;7(1):18-26.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.